Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.05, FiscalAI reports.
Aldeyra Therapeutics Trading Up 1.8%
Shares of Aldeyra Therapeutics stock traded up $0.01 on Friday, hitting $0.63. 252,548 shares of the company traded hands, compared to its average volume of 1,731,283. Aldeyra Therapeutics has a 12-month low of $0.53 and a 12-month high of $5.93. The company has a market cap of $37.82 million, a P/E ratio of -1.61 and a beta of 1.32. The firm’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $2.23.
Analyst Ratings Changes
A number of research firms have weighed in on ALDX. Weiss Ratings lowered Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, September 14th. BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, September 29th. Wall Street Zen lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price objective on shares of Aldeyra Therapeutics in a research note on Wednesday, September 30th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.50.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory signaling molecules that may contribute to ocular and systemic diseases.
Aldeyra’s lead investigational product is reproxalap, an eye drop designed to inhibit RASP activity. The company has studied reproxalap in conditions including dry eye disease and allergic conjunctivitis.
Further Reading
- Five stocks we like better than Aldeyra Therapeutics
- Block by Block: Cash App Builds a Stronger Foundation
- Arista Networks Cashes In on the AI Infrastructure Buildout
- Powering Up: Freeport-McMoRan’s $4.5B Copper Expansion
- 3 Dividend ETFs Offer Different Ways to Navigate the Post-Election Sell-Off
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
